The prognosis for filovirus infection tends to be quite poor with few treatment options and high mortality rates that vary between 30% and 70% with prognosis worsening with increasing patient age and nutritional status.

Promisingly, vaccines have undergone phase II/III clinical trials during the 2014 to 2016 outbreak.